E
CLBT icon

Ergoteles’s Cellebrite CLBT Stock Holding History

Ergoteles’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,400
Closed -$74.9K – 195
2023
Q2 		$74.9K Buy
+10,400
New +$60.6K ﹤0.01% 933
2022
Q3 		– Sell
-34,799
Closed -$177K – 1599
2022
Q2 		$177K Buy
+34,799
New +$181K 0.01% 1371

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.35B AUM 35.86% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
MCM
Makena Capital Management Menlo Park, California $952M AUM 13.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $903M AUM 113.12% 1-Year Est. Return
IP
Isomer Partners New York $74.3M AUM 23.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ergoteles's CLBT Position: Q3 2023 in Review

Ergoteles sold out of Cellebrite (CLBT) in Q3 2023, closing a stake of 10,400 shares — an estimated $74.9K sold.

Ergoteles first reported a position in CLBT in Q2 2022 and held it in 2 quarters. The position peaked at $177K in Q2 2022. 94 funds tracked by Wall St. Rank hold CLBT as of Q3 2023.

  • Ergoteles reported no remaining Cellebrite position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 10,400 Cellebrite shares in Q3 2023, an estimated $74.9K.
  • Ergoteles first reported a position in Cellebrite in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Cellebrite position peaked at $177K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Cellebrite as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.